Overview

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
Phase:
Phase 2
Details
Lead Sponsor:
COMPASS Pathways
Treatments:
Psilocybin